Literature DB >> 29257718

Complete Tumor Response to Pembrolizumab and Allograft Preservation in Renal Allograft Recipient on Immunosuppressive Therapy.

Masood Sadaat1, Sekwon Jang1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29257718     DOI: 10.1200/JOP.2017.027326

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  10 in total

Review 1.  Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.

Authors:  Mark A Perazella; Anushree C Shirali
Journal:  J Am Soc Nephrol       Date:  2018-06-29       Impact factor: 10.121

Review 2.  A review of cancer immunotherapy: from the past, to the present, to the future.

Authors:  K Esfahani; L Roudaia; N Buhlaiga; S V Del Rincon; N Papneja; W H Miller
Journal:  Curr Oncol       Date:  2020-04-01       Impact factor: 3.677

Review 3.  Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response.

Authors:  Enrico Zelin; Carlo Alberto Maronese; Arianna Dri; Ludovica Toffoli; Nicola Di Meo; Gianluca Nazzaro; Iris Zalaudek
Journal:  J Clin Med       Date:  2022-06-11       Impact factor: 4.964

Review 4.  Immunotherapy for Non-melanoma Skin Cancer.

Authors:  Sophia Z Shalhout; Kevin S Emerick; Howard L Kaufman; David M Miller
Journal:  Curr Oncol Rep       Date:  2021-08-27       Impact factor: 5.075

5.  Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review.

Authors:  Kang Miao; Li Zhang
Journal:  Interdiscip Sci       Date:  2021-06-21       Impact factor: 2.233

6.  The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.

Authors:  Vivek Kumar; Atul B Shinagare; Helmut G Rennke; Sandeep Ghai; Jochen H Lorch; Patrick A Ott; Osama E Rahma
Journal:  Oncologist       Date:  2020-02-11

7.  Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.

Authors:  Noha Abdel-Wahab; Houssein Safa; Ala Abudayyeh; Daniel H Johnson; Van Anh Trinh; Chrystia M Zobniw; Heather Lin; Michael K Wong; Maen Abdelrahim; A Osama Gaber; Maria E Suarez-Almazor; Adi Diab
Journal:  J Immunother Cancer       Date:  2019-04-16       Impact factor: 13.751

8.  Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients.

Authors:  Sandhya Manohar; Charat Thongprayoon; Wisit Cheungpasitporn; Svetomir N Markovic; Sandra M Herrmann
Journal:  Kidney Int Rep       Date:  2019-12-07

Review 9.  Immune checkpoint inhibitors to treat cutaneous malignancies.

Authors:  Dulce M Barrios; Mytrang H Do; Gregory S Phillips; Michael A Postow; Tomoko Akaike; Paul Nghiem; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2020-05-24       Impact factor: 11.527

10.  Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation.

Authors:  Khashayar Esfahani; Tho-Alfakar Al-Aubodah; Pamela Thebault; Réjean Lapointe; Marie Hudson; Nathalie A Johnson; Dana Baran; Najwa Bhulaiga; Tomoko Takano; Jean-François Cailhier; Ciriaco A Piccirillo; Wilson H Miller
Journal:  Nat Commun       Date:  2019-10-17       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.